220 related articles for article (PubMed ID: 36468954)
1. Novel Regimen of IL-17A Inhibitor Secukinumab for the Remission of Severe Hidradenitis Suppurativa: Case Report.
Gutierrez E; Issa N; Resnik B
J Drugs Dermatol; 2022 Dec; 21(12):1358-1360. PubMed ID: 36468954
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
4. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.
Stergianou D; Kanni T; Damoulari C; Giamarellos-Bourboulis EJ
Expert Opin Biol Ther; 2024 Apr; 24(4):225-232. PubMed ID: 38602836
[TBL] [Abstract][Full Text] [Related]
6. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
[TBL] [Abstract][Full Text] [Related]
7. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report.
Thorlacius L; Theut Riis P; Jemec GBE
Br J Dermatol; 2018 Jul; 179(1):182-185. PubMed ID: 28654150
[TBL] [Abstract][Full Text] [Related]
8. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
9. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
[TBL] [Abstract][Full Text] [Related]
11. Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab.
Nikolakis G; Kreibich K; Vaiopoulos A; Kaleta K; Talas J; Becker M; Zouboulis CC
F1000Res; 2021; 10():381. PubMed ID: 34540202
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab in the treatment of hidradenitis suppurativa.
Snyder CL; Gibson RS; Porter ML; Kimball AB
Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
[TBL] [Abstract][Full Text] [Related]
13. Target molecules for future hidradenitis suppurativa treatment.
Zouboulis CC; Frew JW; Giamarellos-Bourboulis EJ; Jemec GBE; Del Marmol V; Marzano AV; Nikolakis G; Sayed CJ; Tzellos T; Wolk K; Prens EP
Exp Dermatol; 2021 Jun; 30 Suppl 1():8-17. PubMed ID: 34085329
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
15. New and Emerging Targeted Therapies for Hidradenitis Suppurativa.
Markota Čagalj A; Marinović B; Bukvić Mokos Z
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409118
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
17. Aberrant expression of interleukin-17A in mast cells contributes to the pathogenesis of hidradenitis suppurativa.
Chu CB; Yang CC; Hsueh YY; Chen PC; Hong YK; Kuo YY; Tsai SJ
Br J Dermatol; 2023 Nov; 189(6):719-729. PubMed ID: 37540988
[TBL] [Abstract][Full Text] [Related]
18. Successful control of hidradenitis suppurativa with verapamil: a case report.
Laroche ML; Teste M; Vanoost J; Geniaux H
Fundam Clin Pharmacol; 2019 Feb; 33(1):122-124. PubMed ID: 30025186
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological development in hidradenitis suppurativa.
Matusiak Ł; Jemec GB; Szepietowski JC
Curr Opin Pharmacol; 2019 Jun; 46():65-72. PubMed ID: 31075754
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.
Tas-Aygar G; Gonul M; Ozcan I; Ayli MD; Ertoy-Baydar D
Dermatol Ther; 2020 Nov; 33(6):e14205. PubMed ID: 32829493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]